RxDoctor Payments Data

Sura Ayoub, MD

Internal Medicine · Shenandoah, TXNPI 1770847378

Payments from drug & device makers

$2,879in general payments, 2019–2025

Across 148 payments — averaging $19.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dexcom, Inc.$339
  • Lilly USA, LLC$335
  • Amgen$326
  • Inspire Medical Systems, Inc.$264
  • Novo Nordisk$262
  • AstraZeneca$218
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$2,82098%
  • Education$592%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,879 in reported general payments places this provider in the 80th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$107,900
Medicare patients
240
Services billed
1,078

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide56$68,938
MounjaroTirzepatide28$51,732
JardianceEmpagliflozin34$40,731
TrulicityDulaglutide13$26,220
FarxigaDapagliflozin Propanediol20$18,881
EliquisApixaban17$17,129
JanuviaSitagliptin Phosphate14$16,580
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$11,800
LinzessLinaclotide15$11,275
Icosapent Ethyl25$7,477
Breo ElliptaFluticasone/Vilanterol12$4,469
Rosuvastatin Calcium253$3,636
Levothyroxine Sodium334$3,444
SynthroidLevothyroxine Sodium48$3,406
Ezetimibe106$2,791

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$335$77,95141 claims
Novo NordiskOzempic$262$68,93856 claims
Boehringer IngelheimJardiance$63$40,73134 claims
AstraZenecaFarxiga, Symbicort$218$21,43831 claims
PfizerEliquis$69$17,12917 claims
MerckJanuvia$33$16,58014 claims
GSKTrelegy Ellipta, Breo Ellipta$155$16,26924 claims
AbbVieLinzess, Synthroid$171$14,68163 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Shenandoah

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →